403 related articles for article (PubMed ID: 19118134)
1. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.
Naidu PS; Booker L; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Apr; 329(1):48-56. PubMed ID: 19118134
[TBL] [Abstract][Full Text] [Related]
2. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.
Kinsey SG; Naidu PS; Cravatt BF; Dudley DT; Lichtman AH
Pharmacol Biochem Behav; 2011 Oct; 99(4):718-25. PubMed ID: 21740924
[TBL] [Abstract][Full Text] [Related]
4. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
5. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus.
Schlosburg JE; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Apr; 329(1):314-23. PubMed ID: 19168707
[TBL] [Abstract][Full Text] [Related]
7. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
8. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.
Hasanein P; Shahidi S; Komaki A; Mirazi N
Eur J Pharmacol; 2008 Sep; 591(1-3):132-5. PubMed ID: 18593578
[TBL] [Abstract][Full Text] [Related]
9. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
10. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
Sasso O; Bertorelli R; Bandiera T; Scarpelli R; Colombano G; Armirotti A; Moreno-Sanz G; Reggiani A; Piomelli D
Pharmacol Res; 2012 May; 65(5):553-63. PubMed ID: 22420940
[TBL] [Abstract][Full Text] [Related]
11. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
Jayamanne A; Greenwood R; Mitchell VA; Aslan S; Piomelli D; Vaughan CW
Br J Pharmacol; 2006 Feb; 147(3):281-8. PubMed ID: 16331291
[TBL] [Abstract][Full Text] [Related]
12. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Nasirinezhad F; Jergova S; Pearson JP; Sagen J
Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
[TBL] [Abstract][Full Text] [Related]
13. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.
Naidu PS; Kinsey SG; Guo TL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2010 Jul; 334(1):182-90. PubMed ID: 20375198
[TBL] [Abstract][Full Text] [Related]
14. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
15. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Nozaki C; Markert A; Zimmer A
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1388-96. PubMed ID: 25910421
[TBL] [Abstract][Full Text] [Related]
17. The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms.
Bosier B; Muccioli GG; Lambert DM
Br J Pharmacol; 2013 Jun; 169(4):794-807. PubMed ID: 22970888
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
19. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia.
Lichtman AH; Shelton CC; Advani T; Cravatt BF
Pain; 2004 Jun; 109(3):319-327. PubMed ID: 15157693
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain.
Sagar DR; Kendall DA; Chapman V
Br J Pharmacol; 2008 Dec; 155(8):1297-306. PubMed ID: 18724387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
